TOVX

Theriva Biologics, Inc. is a clinical-stage immuno-oncology company focused on developing oncolytic virus therapeutics designed to selectively target and destroy tumor cells in solid tumors. The company's therapies aim to enhance the effectiveness of existing cancer treatments and provide new options for patients with difficult-to-treat cancers. Theriva's pipeline includes engineered oncolytic viruses that can be administered systemically, with potential applications across various challenging tumor types.